Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 16,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Completed No phase listed Observational

Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)

NCT04295850
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 81 mg
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 60 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 30, 2026, 5:28 AM EDT
Enrolling by invitation No phase listed Observational

Observational Registry for Iltamiocel Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

NCT06743620
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
iltamiocel
Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Harvard, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

NCT01461824
View directory record Official record
Conditions
Weight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 30, 2026, 5:28 AM EDT
Completed No phase listed Observational

Study of Vaginal Dilator Use After Pelvic Radiotherapy

NCT00789893
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Rectal Cancer, Anal Cancer
Interventions
Vaginal Dilator
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 30, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer

NCT03675893
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Letrozole, Abemaciclib, LY3023414, Metformin, Gedatolisib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

Sit Less, Interact and Move More (SLIMM) 2 Study

NCT05173714
View directory record Official record
Conditions
Chronic Kidney Diseases, Obesity
Interventions
SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide
Behavioral · Drug
Lead sponsor
Srinvasan Beddhu
Other
Eligibility
20 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

NCT00340704
View directory record Official record
Conditions
Bladder, Neurogenic
Interventions
tamsulosin hydrochloride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 16 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 30, 2026, 5:28 AM EDT
Recruiting No phase listed Observational

Transformative Research in Diabetic Nephropathy

NCT02986984
View directory record Official record
Conditions
Diabetic Nephropathies, Diabetic Glomerulosclerosis
Interventions
There is no intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 4 Interventional

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

NCT00053547
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Renal Disease
Interventions
paricalcitol injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 30, 2026, 5:28 AM EDT
Withdrawn Phase 3 Interventional

Effect of TXA on Blood Loss in Reverse Total Shoulder Arthroplasty

NCT06638749
View directory record Official record
Conditions
Shoulder Arthritis, Blood Loss, Surgical, Tranexamic Acid Adverse Reaction
Interventions
Tranexamic Acid, Normal Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Compliance With Medical Testing Guidelines

NCT02430948
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colon Cancer, Lung Cancer
Interventions
Color-coded materials, Academic detailing, Standard support, No academic detailing
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
30 Years to 89 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 30, 2026, 5:28 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35

NCT00161226
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Levonorgestrel intrauterine system
Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

NCT02386826
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer, Renal Cell Carcinoma
Interventions
INC280, bevacizumab
Drug · Biological
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 30, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

NCT01663285
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Neoadjuvant Cisplatin and Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

NCT00059735
View directory record Official record
Conditions
Kidney Neoplasms, Carcinoma, Renal Cell, Adenocarcinoma, Renal Cell
Interventions
E7070
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Sacramento, California • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 30, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sight and Hearing Investigation Into Effects on Delirium

NCT06176625
View directory record Official record
Conditions
Hearing Loss, Hearing Loss, Age-Related, Hearing Disability, Delirium, Delirium in Old Age, Delirium of Mixed Origin, Delirium With Dementia, Delirium on Emergence, Delirium, Cause Unknown, Delirium Superimposed on Dementia, Delirium Confusional State, Delirium;Non Alcoholic, Hearing Loss, Bilateral, Hearing Loss, Sensorineural, Hearing Loss, Functional, Hearing Loss, High-Frequency, Hearing
Interventions
Communication Signage, Amplifier Use
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
1,543 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

NCT01188876
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin, pralatrexate, Folic Acid, Vitamin B12 Injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 30, 2026, 5:28 AM EDT
Completed No phase listed Observational

Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer

NCT01117389
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Early Phase 1 Interventional

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

NCT04457089
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Interventions
Simvastatin 40mg
Drug
Lead sponsor
Marc Goodman
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 30, 2026, 5:28 AM EDT
Not listed Phase 2 Interventional

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

NCT02188550
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
everolimus and letrozole
Drug
Lead sponsor
Sinai Hospital of Baltimore
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 30, 2026, 5:28 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850
View directory record Official record
Conditions
Chronic Kidney Disease; Iron Deficiency Anemia
Interventions
Ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 30, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers

NCT00666991
View directory record Official record
Conditions
Peritoneal Neoplasms
Interventions
nanoparticulate paclitaxel
Drug
Lead sponsor
CritiTech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Kansas City, Kansas • Wichita, Kansas • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 30, 2026, 5:28 AM EDT
Recruiting Phase 1 Interventional

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

NCT07103018
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
KTX-2001, KTX-2001 + Darolutamide (NUBEQA®)
Drug
Lead sponsor
K36 Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
San Francisco, California • Miami, Florida • Port Saint Lucie, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 5:28 AM EDT